Clinical Research Directory
Browse clinical research sites, groups, and studies.
Losartan for Corneal Fibrosis
Sponsor: Universidad Autonoma de Nuevo Leon
Summary
This is a prospective, randomized, double-blinded, controlled clinical trial designed to evaluate the efficacy and safety of topical losartan in improving visual acuity, contrast sensitivity and reducing corneal densitometry, corneal aberrations and corneal scarring severity in adult patients with corneal scars of different etiologies. Participants will be randomly assigned to receive either topical losartan 0.8 mg/mL or placebo eyedrops 6 times per day for six months.
Official title: Topical Losartan as Treatment to Reduce Corneal Scarring Fibrosis
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
46
Start Date
2026-02-12
Completion Date
2027-03-01
Last Updated
2026-03-04
Healthy Volunteers
No
Conditions
Interventions
Topical losartan
Drug: Topical Losartan 0.8 mg/ml ophthalmic solution, one drop applied six times daily for six months.
Placebo Control
Drug: Balanced saline solution ophthalmic drops, one drop applied six times daily for six months.
Locations (1)
Ophthalmology Department
Monterrey, Nueo Leon, Mexico